Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result

Описание к видео Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result

CNBC’s Angelica Peebles and Eli Lilly chairman and CEO David Ricks join 'Squawk on the Street' to discuss results of the company's 3-year obesity study, which showed its highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo.

Комментарии

Информация по комментариям в разработке

Похожие видео